



MEMORANDUM

Date: August 21, 2020

From: Marie J. Anderson
Quality Assurance Branch (QAB)
Division of Biological Standards and Quality Control (DBSQC)
Office of Compliance and Biologics Quality (OCBQ)
Center for Biologics Evaluation and Research (CBER)
Food and Drug Administration (FDA)

To: Biologics License Application Submission Tracking Numbers 125706

Subject: Review of the Lot Release Protocol (LRP) template for Ex Vivo Cultured Adult Human Mesenchymal Stem Cells for the treatment of acute Graft versus Host Disease (aGvHD) in pediatric patients, when the aGvHD has been refractory to treatment with systemic corticosteroid therapy (SR-aGVHD).

Through: Maryna Eichelberger, PhD, Director, DBSQC/OCBQ/CBER/FDA
Varsha Garnepudi, Acting Branch Chief, QAB/DBSQC/OCBQ/CBER/FDA

Cc: Matthew Klinker, PhD, Chair, BLA Review Committee,
DCGT/OTAT/CBER/FDA
Adriane Fisher, Regulatory Project Manager, DRPM/OTAT/CBER/FDA
Edward Thompson, Regulatory Project Manager, DRPM/OTAT/CBER/FDA

Applicant: Mesoblast Inc.

Product: Ex Vivo Cultured Adult Human Mesenchymal Stem Cells
Trade-name: Ryoncil

1 General Information

1.1 CMC Review Identifiers and Dates

1.1.1 **Biologics License Application (BLA) Submission Tracking Number (STN):**
125706

1.1.2 **Submission received by CBER:** January 31, 2020

1.1.3 **Review completed:** Incomplete due to the issuance of a complete response letter.

1.1.4 **Material Reviewed:**

BLA 125706

1.1.5 **Related Master File, INDs and BLAs:**

IND 7939

IND (b) (4)

2 Executive Summary: The LRP template for Ex Vivo Cultured Adult Human Mesenchymal Stem Cells submitted in amendment 125706/0.30 on June 5, 2020 is incomplete. The review will be completed when the issues identified in the complete response letter have been addressed.

3 Review

3.1 Documents Reviewed

LRP template for Ex Vivo Cultured Adult Human Mesenchymal Stem Cells submitted in amendment 125706/0.30 on June 5, 2020

3.2 Review

On January 30, 2020 Mesoblast Inc. submitted BLA 125706 for Ex Vivo Cultured Adult Human Mesenchymal Stem Cells. An LRP template was requested in an IR sent on May 5, 2020.

Mesoblast Inc. submitted the LRP template in amendment 125706/0.30 on June 5, 2020. The LRP template review has not been completed by representatives of OTAT/DCGT, OCBQ/DBSQC and OCBQ/DMPQ.

3.3 Conclusions

The review of the LRP template received June 5, 2020 in amendment 125706/0.30 will be completed when the issues identified in the complete response letter have been addressed.